Regulatory

Regulatory  ·  Weekly Digest - 04 July to 10 July
China’s NMPA administration accepts Biologics License Application for PADCEV plus Keytruda in Muscle-Invasive Bladder Cancer

Weekly Digest – July 2026 Weekly Digest – July 2026 7 July 2026: China’s NMPA administration accepts Biologics License Application for PADCEV plus Keytruda in Muscle-Invasive Bladder Cancer Astellas have announced that China’s National Medical Products Administration has accepted the […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 04 July to 10 July
Hengrui ADC innovative drug Ruikang Trastuzumab new indication marketing application accepted and included in priority review

Weekly Digest – July 2026 Weekly Digest – July 2026 8 July 2026: Hengrui ADC innovative drug Ruikang Trastuzumab new indication marketing application accepted and included in priority review Hengrui Pharma’s HER2-targeted antibody-drug conjugate Trastuzumab rezetecan has had its new […]

by Sandhya Ramalingam

Continue Reading